查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726347

全球细胞再程式化市场：市场规模、份额、趋势分析（按技术、应用、最终用途和地区）、细分市场预测（2025-2030 年）

Cell Reprogramming Market Size, Share & Trends Analysis Report By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

细胞再程式化市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球细胞再程式化市场规模预计到2030年将达到6.642亿美元，2025年至2030年的复合年增长率为8.55%。

预计癌症研究中越来越多地采用细胞再程式化以及对细胞再程式化的日益关注等因素将推动市场成长。此外，重点关注合作研究和主要企业之间的伙伴关係预计将推动市场成长。 mRNA再程式化技术的进步将能够从体细胞组织快速、安全、有效率地产生临床级人类 iPS 细胞。此外，由于mRNA的尺寸较小，转染过程比其他重编程载体更容易。当利用难以再程式化的样本时，mRNA再程式化可以将再程式化效率提高1%。

此外，对 mRNA 重编程技术的需求日益增加，因为这种方法可以更快、更安全地从体细胞组织中产生高品质的人类 iPS 细胞。此外，它还能够将人类干细胞重新编程为幼稚状态，重现最早的发育阶段。例如，2022 年 3 月，巴布拉汉研究所的研究人员发现了加速这个初始化过程的关键因素。这项新发现使研究人员能够简化和加速幼稚多功能细胞的生成。此外，在政府和公共资金的大力推动下，细胞重编程正在蓬勃发展。这种支持是对其为医疗保健行业带来的各种好处的回应，特别是在潜在的医疗应用方面。

此外，细胞再程式化最近已被研究人员从实验室重新定位到临床。这种变化在各种临床和学术研究领域都很明显，包括与再生医学、疾病建模、药物毒性和药物发现相关的领域。细胞再程式化的临床效用在再生医学中特别明显。越来越多的旨在透过细胞再程式化开发创新产品的策略性倡议正在推动研究和学术领域的成长。例如，加州再生医学研究所正在资助研究小组，以推动细胞再程式化应用于临床治疗。

细胞再程式化市场报告重点

  • mRNA再程式化技术领域预计将在 2024 年占据最大的收益占有率，达到 32.63%，因为它易于使用、速度快、安全高效，同时可以从体细胞组织中生成高品质的人类 iPS 细胞。
  • 2024 年，研究应用领域占据市场主导地位，份额为 67.30%。成长的主要驱动力之一是利用干细胞进行细胞再程式化领域的持续研究。
  • 研究和学术机构最终用途部门在 2024 年的收入份额为 67.30%。这一增长是由细胞再程式化在各种临床和学术研究计划中的应用所推动的，包括再生疗法、疾病建模和药物毒性/药物发现研究。
  • 由于北美地区拥有领先公司，因此在 2024 年占据了全球行业的主导地位，收入份额为 39.69%。

目录

第一章 分析方法与范围

第二章执行摘要

第三章 市场驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19影响分析

第四章 按技术进行的业务分析

  • 技术仪表板
  • 细胞再程式化市场：依技术进行差异分析
  • 基于仙台病毒的再程式化
    • 仙台病毒重再程式化市场（2018-2030）
  • mRNA再程式化
    • mRNA再程式化市场（2018-2030）
  • 游离重再程式化
    • 表观遗传学再程式化市场（2018-2030）
  • 其他的
    • 其他再程式化市场（2018-2030）

第 5 章 按应用程式进行的业务分析

  • 特定于应用程式的仪表板
  • 细胞再程式化市场：依应用进行的变化分析
  • 研究
    • 研究市场（2018-2030）
  • 治疗
    • 治疗市场（2018-2030）

第六章 以最终用途分類的业务分析

  • 按最终用途分類的仪表板
  • 细胞再程式化市场：依最终用途的变化分析
  • 研究和学术机构
    • 研究与学术机构市场（2018-2030）
  • 生物技术和製药公司
    • 生物技术和製药市场（2018-2030）

第七章区域业务分析

  • 区域仪表板
  • 各地区细胞再程式化市场占有率（2018-2030）
  • 北美洲
    • 北美细胞再程式化市场（2018-2030）
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲细胞再程式化市场（2018-2030）
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太细胞再程式化市场（2018-2030）
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 拉丁美洲细胞再程式化市场（2018-2030）
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲细胞再程式化市场（2018-2030）
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 公司分类
  • 战略地图
  • 企业市场分析
  • 公司简介/上市公司
    • Thermo Fisher Scientific, Inc.
    • Allele Biotechnology and Pharmaceuticals Inc.
    • ALSTEM
    • STEMCELL Technologies
    • Merck KGaA
    • Bio-Techne
    • REPROCELL Inc.
    • Lonza
    • FUJIFILM Corporation（Fujifilm Cellular Dynamics）
    • Mogrify Limited
Product Code: GVR-4-68039-966-2

Cell Reprogramming Market Growth & Trends:

The global cell reprogramming market size is estimated to reach USD 664.2 million by 2030, registering a CAGR of 8.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. Factors, such as increasing adoption of cell reprogramming in cancer research and growing focus on cell reprogramming, are expected to drive market growth. In addition, emphasis on collaborations and partnerships among key players is anticipated to boost market growth. Advancements in the mRNA reprogramming technique allow rapid, safe, and efficient generation of clinical-grade human iPS cells using somatic tissue. In addition, as mRNA is lower in size, the transfection process is simpler than other reprogramming vectors. When utilizing difficult-to-reprogram samples, mRNA reprogramming improves reprogramming efficiency by 1%.

Furthermore, this method can generate high-quality human iPS cells from somatic tissue more rapidly and safely, which increases the demand for mRNA reprogramming technology. Furthermore, there is the capability to reprogram human stem cells back to a naive state, allowing replication of the earliest developmental stages. For instance, in March 2022, researchers at the Babraham Institute identified key factors facilitating this reprogramming process. This new knowledge streamlines and expedites the generation of naive pluripotent stem cells for researchers. Moreover, cell reprogramming is experiencing growth due to significant government and public funding. This backing is a response to various benefits it offers to the healthcare sector, particularly in terms of its potential applications in medicine.

Furthermore, cell reprogramming has recently been repositioned from the lab to clinic by researchers. This shift is prominent in various clinical & academic research initiatives, encompassing regenerative medicine, disease modeling, and studies related to medication toxicity & drug discovery. The clinical utility of cell reprogramming, especially in regenerative medicine, has been significant. Increased strategic initiatives aimed at innovative product development through cell reprogramming is due to a growth in the research and academic institute segment. For instance, the California Institute for Regenerative Medicine funded research groups to advance cellular reprogramming into therapeutic applications with a clinical focus.

Cell Reprogramming Market Report Highlights:

  • The mRNA reprogramming technology segment held the largest revenue share of 32.63% in 2024, due to the ease of use, speed, safety, and efficiency while generating high-quality human iPS cells from somatic tissue.
  • The research application segment led the market with a share of 67.30% in 2024. One of the main factors driving its growth include ongoing research in the field of cell reprogramming using stem cells.
  • The research & academic institute end-use segment held a revenue share of 67.30% in 2024. The growth is due to usage of cell reprogramming in a various clinical & academic research initiatives, including those involving regenerative therapies, disease modeling, and drug toxicity/drug discovery studies.
  • North America dominated the global industry in 2024, with a revenue share of 39.69%, owing to the presence of key players in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Information Analysis
    • 1.2.2. Market Platform & Data Visualization
    • 1.2.3. Data Validation & Publishing
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Platform & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1:
    • 1.9.2. Objective 2:

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing focus on cell reprogramming
      • 3.2.1.2. Increasing adoption of cell reprogramming in cancer research
      • 3.2.1.3. Emphasis on collaborations and partnerships among key players
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Challenges associated with iPSCs
      • 3.2.2.2. Limited awareness regarding treatment option
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

  • 4.1. Technology Segment Dashboard
  • 4.2. Cell Reprogramming Market: Technology Movement Analysis
  • 4.3. Sendai Virus-based Reprogramming
    • 4.3.1. Sendai Virus-based Reprogramming Market, 2018 - 2030 (USD Million)
  • 4.4. mRNA Reprogramming
    • 4.4.1. mRNA Reprogramming Market, 2018 - 2030 (USD Million)
  • 4.5. Episomal Reprogramming
    • 4.5.1. Episomal Reprogramming Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Reprogramming Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. Cell Reprogramming Market: Application Movement Analysis
  • 5.3. Research
    • 5.3.1. Research Market, 2018 - 2030 (USD Million)
  • 5.4. Therapeutics
    • 5.4.1. Therapeutics Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. Cell Reprogramming Market: End-use Movement Analysis
  • 6.3. Research & Academic Institutes
    • 6.3.1. Research & Academic Institutes Market, 2018 - 2030 (USD Million)
  • 6.4. Biotechnology & Pharmaceutical Companies
    • 6.4.1. Biotechnology & Pharmaceutical Companies Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Regional Dashboard
  • 7.2. Cell Reprogramming Market Share by Region, 2018- 2030
  • 7.3. North America
    • 7.3.1. North America Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. U.S. Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Canada Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Mexico Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. UK Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Germany Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. France Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Italy Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Spain Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Denmark Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Sweden Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Norway Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Japan Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. China Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. India Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Australia Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Thailand Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. South Korea Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Brazil Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Argentina Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. South Africa Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Saudi Arabia Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. UAE Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Kuwait Cell Reprogramming Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis
  • 8.4. Company Profiles/Listing
    • 8.4.1. Thermo Fisher Scientific, Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Allele Biotechnology and Pharmaceuticals Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. ALSTEM
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. STEMCELL Technologies
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Merck KGaA
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Bio-Techne
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. REPROCELL Inc.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Lonza
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. FUJIFILM Corporation (Fujifilm Cellular Dynamics)
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Mogrify Limited
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 4 Global Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 5 Global Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 6 Global Cell Reprogramming Market, By Region, 2018 - 2030 (USD Million)
  • Table 7 North America Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 9 North America Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 10 North America Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 11 U.S. Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 13 U.S. Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 14 Canada Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 15 Canada Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 16 Canada Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 17 Mexico Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 18 Mexico Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 19 Mexico Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 20 Europe Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 22 Europe Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 23 Europe Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 24 UK Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 25 UK Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 26 UK Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 27 Germany Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 28 Germany Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 29 Germany Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 30 France Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 31 France Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 32 France Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 33 Spain Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 34 Spain Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 35 Spain Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 36 Italy Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 37 Italy Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 38 Italy Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 39 Denmark Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 40 Denmark Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 41 Denmark Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 42 Norway Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 43 Norway Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 44 Norway Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 45 Sweden Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 46 Sweden Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 47 Sweden Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 52 China Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 53 China Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 54 China Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 55 Japan Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 56 Japan Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 57 Japan Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 58 India Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 59 India Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 60 India Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 61 South Korea Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 62 South Korea Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 63 South Korea Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 64 Australia Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 65 Australia Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 66 Australia Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 67 Thailand Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 68 Thailand Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 69 Thailand Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 70 Latin America Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 72 Latin America Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 73 Latin America Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 74 Brazil Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 75 Brazil Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 76 Brazil Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 77 Argentina Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 78 Argentina Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 79 Argentina Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 80 MEA Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 81 MEA Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 82 MEA Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 83 MEA Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 84 South Africa Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 85 South Africa Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 86 South Africa Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 87 UAE Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 88 UAE Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 89 UAE Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 92 Saudi Arabia Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Cell Reprogramming market segmentation
  • Fig. 8 Market snapshot
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 PESTEL analysis
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Global cell reprogramming market: Technology outlook and key takeaways
  • Fig. 15 Global cell reprogramming market: Technology movement analysis
  • Fig. 16 Global cell reprogramming market, for sendai virus-based reprogramming, 2018 - 2030 (USD Million)
  • Fig. 17 Global cell reprogramming market, for mRNA reprogramming, 2018 - 2030 (USD Million)
  • Fig. 18 Global cell reprogramming market, for episomal reprogramming, 2018 - 2030 (USD Million)
  • Fig. 19 Global cell reprogramming market, for others, 2018 - 2030 (USD Million)
  • Fig. 20 Global cell reprogramming market: Application outlook and key takeaways
  • Fig. 21 Global cell reprogramming market: Application movement analysis
  • Fig. 22 Global cell reprogramming market, for research, 2018 - 2030 (USD Million)
  • Fig. 23 Global cell reprogramming market, for therapeutic, 2018 - 2030 (USD Million)
  • Fig. 24 Global cell reprogramming market: End-use outlook and key takeaways
  • Fig. 25 Global cell reprogramming market: End-use movement analysis
  • Fig. 26 Global cell reprogramming market, for research & academic institutes, 2018 - 2030 (USD Million)
  • Fig. 27 Global cell reprogramming market, for biotechnology & pharmaceutical companies, 2018 - 2030 (USD Million)
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 Regional outlook, 2022 & 2030
  • Fig. 30 North America cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Key country dynamics
  • Fig. 32 U.S. cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Key country dynamics
  • Fig. 34 Canada cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico Key country dynamics
  • Fig. 36 Mexico cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany Key country dynamics
  • Fig. 39 Germany cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 40 UK Key country dynamics
  • Fig. 41 UK cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 42 France Key country dynamics
  • Fig. 43 France cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy Key country dynamics
  • Fig. 45 Italy cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 46 Spain Key country dynamics
  • Fig. 47 Spain cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark Key country dynamics
  • Fig. 49 Denmark cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 50 Sweden Key country dynamics
  • Fig. 51 Sweden cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 52 Norway Key country dynamics
  • Fig. 53 Norway cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 55 Japan Key country dynamics
  • Fig. 56 Japan cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 57 China Key country dynamics
  • Fig. 58 China cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 59 India Key country dynamics
  • Fig. 60 India cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 61 Australia Key country dynamics
  • Fig. 62 Australia cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 63 South Korea Key country dynamics
  • Fig. 64 South Korea cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 65 Thailand Key country dynamics
  • Fig. 66 Thailand cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil Key country dynamics
  • Fig. 69 Brazil cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina Key country dynamics
  • Fig. 71 Argentina cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 72 Middle East and Africa cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 73 South Africa Key country dynamics
  • Fig. 74 South Africa cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 75 Saudi Arabia Key country dynamics
  • Fig. 76 Saudi Arabia cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 77 UAE Key country dynamics
  • Fig. 78 UAE cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 79 Kuwait Key country dynamics
  • Fig. 80 Kuwait cell reprogramming market, 2018 - 2030 (USD Million)